BioSenic S.A. (0R55.L)
| Previous close | 0.1420 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | N/A |
| Market cap | 14,267 |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7670 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
BioSenic delivers a new post-hoc analysis of its Phase III JTA-004 trial on knee osteo-arthritis with positive action on the most severely affected patient population
REGULATED INFORMATION New analysis and formal identification of patient subsets open up further potential clinical development options for JTA-004 Mont-Saint-Guibert, Belgium, March 16, 2023, 7am CET - BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in severe autoimmune/inflammatory diseases and cellular repair, announces today it has re-evaluated the results of its Phase III trial of its enhanced viscosupplement JTA-004 targeting knee osteoarthritis (OA). B
- Globe Newswire
BioSenic SA: Information on the total number of voting rights and shares
REGULATED INFORMATION Mont-Saint-Guibert, Belgium, March 1st, 2023, 6.00pm CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the innovative company addressing unmet medical needs in in the areas of innate immunity, inflammation and organ/function repair, today announces an update in the total number of voting rights and shares. The following information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the publication of major shareholdings in issuers whose shares
- Globe Newswire
BioSenic optimizes statistical analysis for its ongoing ALLOB Phase IIb study for high-risk tibial fractures, requiring fewer patients and completes patient recruitment
Combination of advances in radiological assessments, new scientific insights in fracture healing and updated statistical analysis results in fewer patients needed for trial, and an earlier readout of relevant results, leading to significant reduction in trial time and costs Decisive statistical analysis results on primary endpoint now expected in Q2 2023 ALLOB subscription rights to become exercisable if the trial RUST score difference is higher than 1.26 in the statistical analysis at month thr
